Research outlook

Where heart failure treatment is heading

Heart failure · Updated Nov 15, 2026

About 6.7 million Americans live with heart failure. When the heart pumps weakly (reduced ejection fraction), four drug classes together lower death and hospital stays: ARNI or ACE/ARB, beta-blockers, MRAs and SGLT2 inhibitors. When pumping is preserved (HFpEF), SGLT2 inhibitors and now finerenone help, and weight-loss drugs help people with obesity. Research is targeting aldosterone, inflammation and obesity, testing long-acting injections, and repairing leaky valves with catheters.

  1. Now

    Nov 2026

    New drugs for preserved pumpingHappened 9.9% death or worsening HF

    Finerenone cut worsening heart failure events (842 vs 1,024); tirzepatide lowered death or worsening heart failure in obesity (9.9% vs 15.3%).

    9.9%: had cardiovascular death or worsening heart failure, vs 15.3% with placebo.

    Old drugs, new evidenceHappened 39.5% died or hospitalized

    Digitoxin lowered death or hospitalization (39.5% vs 44.1%); IV iron gave a modest benefit; strict fluid limits did not improve wellbeing.

    39.5%: died or were hospitalized for heart failure, vs 44.1% with placebo.

    Fixing leaky tricuspid valvesHappened 52.4% event-free at 3 years

    Catheter repair kept 52.4% free of death or heart failure hospitalization at 3 years vs 21.0%.

    52.4%: free of death or heart failure hospitalization at 3 years, vs 21.0%.

  2. 6 months

    by May 2027

    Calming inflammationLikely

    Novo Nordisk's ATHENA (673 people) tests ziltivekimab, an IL-6 antibody, on symptoms and function in HFpEF with inflammation; due October 2026.

    A new MRA combined with dapagliflozinPossible

    AstraZeneca's BalanceD-HF (3,850 people) tests balcinrenone plus dapagliflozin in heart failure with kidney impairment; due April 2027.

  3. 12 months

    by Nov 2027

    Finerenone in hospital and with SGLT2 drugsPossible 842 worsening HF events

    REDEFINE-HF (5,200 people) starts finerenone during a hospital stay; CONFIRMATION starts it with empagliflozin. Both due November 2027.

    842: worsening heart failure events with finerenone, vs 1,024 with placebo.

    A heart-muscle booster returnsPossible

    Cytokinetics' COMET-HF (1,800 people) tests omecamtiv mecarbil in severely reduced pumping; due September 2027.

  4. 3 years

    by late 2029

    Blocking aldosterone productionPossible

    Boehringer's vicadrostat plus empagliflozin trials (10,900 people) report from May 2028.

    A monthly weight-loss shot for HFpEFPossible 9.9% death or worsening HF (tirzepatide)

    Amgen's MARITIME-HF (5,056 people) tests maridebart cafraglutide in HFpEF and HFmrEF with obesity; due June 2028.

    9.9%: had cardiovascular death or worsening heart failure with tirzepatide, vs 15.3%.

  5. 5 years

    by late 2031

    Preventing heart failurePossible

    AstraZeneca's Prevent-HF (11,300 people, due December 2029) tests baxdrostat with dapagliflozin in people at risk.

    Pills and new weight drugs for outcomesPossible

    Elevate-HF (elecoglipron pill, due September 2029) and HF-POLARIS (due July 2029) test whether newer obesity drugs reduce heart failure events.

    Clearing amyloid from the heartLong shot

    Novo Nordisk's CLEOPATTRA (1,280 people, due June 2029) tests coramitug, an antibody that removes ATTR amyloid deposits.

Happened Likely Possible Long shot

The research paths

Heating up

Aldosterone and MRA drugs

842 worsening HF events
Details and 8 trialsHide
Heating up

Obesity drugs for the heart

9.9% death or worsening HF
Details and 3 trialsHide
Early

Inflammation and heart muscle

Details and 3 trialsHide
Maturing

Devices and valves

52.4% event-free at 3 years
DetailsHide

Catheter valve repair, shunts and other procedures for people still struggling on medicines.

WatchLonger follow-up of tricuspid repair.

Borrowed from other conditions

From Diabetes and obesity

Tirzepatide and semaglutide

Approved for other uses

Weight-loss drugs that improved symptoms and outcomes in obesity-related HFpEF.

From Resistant high blood pressure

Baxdrostat and vicadrostat

Phase 3

Aldosterone synthase inhibitors first developed to lower hard-to-treat blood pressure.

From Kidney disease and heart attack prevention

Ziltivekimab

Phase 3

An IL-6 antibody also tested to lower heart risk in chronic kidney disease.

Open to join now

See every recruiting Heart failure trial →

When the trials finish

Completion dates the trials registered. Results usually follow 3 to 12 months later.

2026202720282029203020312032Today
Oct 2026
Spironolactone in HFpEF (SPIRRIT)Aldosterone and MRA drugs
Dec 2026
Apr 2027
Sep 2027
Nov 2027
Nov 2027
Vicadrostat plus empagliflozinAldosterone and MRA drugs
May 2028
Jun 2028
Feb 2029
Jun 2029
Jul 2029
Sep 2029

What just happened

Ziltivekimab outcomes trial HERMES listed as terminated

ClinicalTrials.gov record.

Tricuspid valve repair cuts death or hospitalization

TRIC-I-HF, NEJM.

Digitoxin lowers death or hospitalization in HFrEF

DIGIT-HF, NEJM.

Standard treatment today

How to read this page, and sourcesHow to read this page, and sources

See Heart failure trials recruiting now →

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.